Waselenko J K, Dawson N A
Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, DC, USA.
Oncology (Williston Park). 1997 Oct;11(10):1551-60; discussion 1560-3, 1567-8.
Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men. While the response of patients with metastatic prostate cancer to initial hormonal manipulation is excellent, the majority of patients eventually progress. As a result, a growing number of patients and their physicians need-to-find acceptable therapeutic alternatives. Fortunately, the number of therapies in the management armamentarium is growing and includes: alternative hormonal therapies, chemotherapy, radioisotopes, and investigational agents. The major focus of treatment has shifted to palliation and quality of life. The decline of prostate-specific antigen (PSA) has become another important end point as evidence supporting a correlation with prolonged survival mounts. Enrolling eligible patients in clinical trials is critical to the development of new treatment strategies for this difficult disease.
转移性前列腺癌是一个日益严重的健康问题，是男性癌症死亡的第二大主要原因。虽然转移性前列腺癌患者对初始激素治疗的反应良好，但大多数患者最终会病情进展。因此，越来越多的患者及其医生需要寻找可接受的治疗替代方案。幸运的是，治疗手段的数量在不断增加，包括：替代激素疗法、化疗、放射性同位素和研究性药物。治疗的主要重点已转向缓解症状和提高生活质量。随着支持前列腺特异性抗原（PSA）下降与延长生存期相关的证据越来越多，PSA的下降已成为另一个重要的终点。让符合条件的患者参加临床试验对于开发针对这种难治性疾病的新治疗策略至关重要。
